Cost-Cutting Sanofi Resumes Fitusiran Studies, Starts COVID Vaccine Phase IIb This Month
2020 Revenues Led By Dupixent, Vaccines
Dupixent was Sanofi’s top-selling product in 2020, but its vaccines division also saw significant growth in the year led by its differentiated influenza vaccines, which helped drive the big pharma’s business during the year, accompanied by significant cost savings.
You may also be interested in...
ABL Bio’s $1.06bn license deal with Sanofi for Parkinson's antibody is seen offering favorable terms to Korean biotech and is also poised to beef up French group’s presence in the space versus competitors.
In a series of articles, Scrip takes a look at some of the key novel products expected to reach the market in 2022 in a cross-section of therapy areas. Here, with input from Biomedtracker, are five new hematology products that could make their market debuts (or return) next year.
The French drugmaker has halted a pivotal trial of venglustat in autosomal dominant polycystic kidney disease, a few months after the drug failed as a treatment for Parkinson’s disease. Sanofi will go back to focusing on the therapy's potential in lysosomal storage diseases.